UK cost agency backs Medivation, Astellas prostate cancer pill

LONDON (Reuters) - Britain's healthcare cost watchdog NICE has recommended that a new prostate cancer pill from Medivation and Astellas should be used on the state health service. The draft guidance is conditional on Xtandi being provided at an undisclosed discount to the list price of 2,734.67 pounds ($4,400) for 28 days supply, the National Institute for Health and Clinical Excellence (NICE) said on Friday. Xtandi, known chemically as enzalutamide, is designed to treat advanced prostate cancer in patients who have previously received chemotherapy. ...



via Health News Headlines - Yahoo! News http://news.yahoo.com/uk-cost-agency-backs-medivation-astellas-prostate-cancer-230237668--sector.html